Rha, Sun YoungSun YoungRhaOh, Do-YounDo-YounOhYañez, PatricioPatricioYañezBai, YuxianYuxianBaiRyu, Min-HeeMin-HeeRyuLee, JeeyunJeeyunLeeRivera, FernandoFernandoRiveraAlves, Gustavo VasconcelosGustavo VasconcelosAlvesGarrido, MarceloMarceloGarridoShiu, Kai-KeenKai-KeenShiuFernández, Manuel GonzálezManuel GonzálezFernándezLi, JinJinLiLowery, Maeve AMaeve ALoweryÇil, TimuçinTimuçinÇilCruz, Felipe MeloFelipe MeloCruzQin, ShukuiShukuiQinLuo, SuxiaSuxiaLuoPan, HongmingHongmingPanWainberg, Zev AZev AWainbergYin, LinaLinaYinBordia, SonalSonalBordiaBhagia, PoojaPoojaBhagiaWyrwicz, Lucjan SLucjan SWyrwiczKUN-HUEI YEH2023-12-142023-12-142023-1114702045https://scholars.lib.ntu.edu.tw/handle/123456789/637872PD-1 inhibitors combined with chemotherapy have shown efficacy in gastric or gastro-esophageal junction cancer. We compared the efficacy and safety of pembrolizumab plus chemotherapy with placebo plus chemotherapy in participants with locally advanced or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma.enPembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trialjournal article10.1016/S1470-2045(23)00515-6378751432-s2.0-85175241348https://api.elsevier.com/content/abstract/scopus_id/85175241348